Human Immunodeficiency Virus Clinical Trials

59 recruitingLast updated: June 18, 2026

There are 59 actively recruiting human immunodeficiency virus clinical trials across 34 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4. Top locations include Cape Town, Western Cape, South Africa, Chicago, Illinois, United States, Durban, KwaZulu-Natal, South Africa. Updated daily from ClinicalTrials.gov.


Human Immunodeficiency Virus Trials at a Glance

59 actively recruiting trials for human immunodeficiency virus are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Not Applicable with 22 trials, with the heaviest enrollment activity in Cape Town, Chicago, and Durban. Lead sponsors running human immunodeficiency virus studies include Merck Sharp & Dohme LLC, University of California, San Francisco, and Johns Hopkins University.

Browse human immunodeficiency virus trials by phase

Treatments under study

About Human Immunodeficiency Virus Clinical Trials

Looking for clinical trials for Human Immunodeficiency Virus? There are currently 24 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Human Immunodeficiency Virus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Human Immunodeficiency Virus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 59 trials

Recruiting

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

Castleman's DiseaseKaposi's SarcomaHuman Immunodeficiency Virus+1 more
National Cancer Institute (NCI)280 enrolled1 locationNCT03300830
Recruiting
Phase 2

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

Merkel Cell CarcinomaMalignant NeoplasmAcquired Immunodeficiency Syndrome+5 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02479698
Recruiting

Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study

Human Immunodeficiency Virus (HIV) -1 infectionHIV-1 Subtype A6 InfectionHIV-1 Subtype B Infection+1 more
Pomeranian Medical University Szczecin250 enrolled7 locationsNCT07370649
Recruiting
Phase 2

Boosting Olfactory and Sensory Training Study (BOOST)

HIV (Human Immunodeficiency Virus)
University of Alabama at Birmingham80 enrolled1 locationNCT07221123
Recruiting
Phase 3

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,390 enrolled81 locationsNCT07044297
Recruiting
Phase 2Phase 3

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC570 enrolled56 locationsNCT07266831
Recruiting
Not Applicable

Gut Microbiota-Mediated Inflammatory Interactions Between AUD and HIV Infection

Alcohol Use DisorderHuman Immunodeficiency Virus
Rush University Medical Center40 enrolled1 locationNCT06139224
Recruiting
Not Applicable

Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India

Cervical CancerHuman Papillomavirus (HPV) InfectionHuman Immunodeficiency Virus (HIV) Infection
University of California, Irvine348 enrolled3 locationsNCT07209917
Recruiting
Phase 3

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,580 enrolled30 locationsNCT07071623
Recruiting
Not Applicable

HIV Testing Counselor-led Care to Catalyze Integration of PrEP Delivery in Family Planning Clinics

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
University of Washington30,000 enrolled1 locationNCT07089966
Recruiting
Not Applicable

The Effects of Chiropractic Care on Inflammation and Quality of Life in People Living With HIV

Human Immunodeficiency Virus (HIV)
Tyson Perez, DC, PhD40 enrolled1 locationNCT07466836
Recruiting
Phase 2

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

HIV (Human Immunodeficiency Virus)MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Naga P. Chalasani120 enrolled10 locationsNCT07143968
Recruiting
Not Applicable

Integrated Mental Health Care for Pregnant Women With HIV in Kenya: The Tunawiri Study

Human Immunodeficiency VirusMental Disorder
University of Colorado, Denver900 enrolled1 locationNCT06117163
Recruiting
Not Applicable

Integrating HIV Prevention With TB Household Contact Evaluation in Uganda

Tuberculosis (TB)Human Immunodeficiency Virus (HIV) Prophylaxis
University of Washington2,480 enrolled1 locationNCT07119359
Recruiting
Phase 3

Cefixime Clinical Trial

Human Immunodeficiency VirusSyphilis
University of Southern California400 enrolled1 locationNCT04958122
Recruiting
Phase 2

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Human Immunodeficiency Virus (HIV) Infection
Merck Sharp & Dohme LLC84 enrolled24 locationsNCT04375800
Recruiting

Harm Reduction in HIV Primary Care for PLWH Who Use Drugs

Substance UseHuman Immunodeficiency VirusStigma, Social
University of Pittsburgh768 enrolled3 locationsNCT05404750
Recruiting
Phase 1

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

Human Immunodeficiency Virus
National Institute of Allergy and Infectious Diseases (NIAID)50 enrolled1 locationNCT06819176
Recruiting
Not Applicable

Adaptation and Implementation of an Evidence-based Approach to Advance HIV Prevention and Care

HIV (Human Immunodeficiency Virus)StigmaContinuum of Care
University of California, Los Angeles80 enrolled1 locationNCT07495059
Recruiting
Phase 1

HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong

Human Immunodeficiency VirusHuman Immunodeficiency Virus I Infection
Immuno Cure Holding (HK) Limited22 enrolled1 locationNCT07530198